Table 1.
Baseline characteristics of all patients (n = 117) and subentities of nonischemic cardiomyopathy
| All, n = 117 | DCM, n = 91 | PPCM, n = 20 | Myocarditis, n = 6 | |
|---|---|---|---|---|
| Male sex | 64 (56) | 62 (68) | 0 (0) | 3 (50) |
| Age, y | 51 ± 15 (95% CI: 49–54) | 55 ± 14 (95% CI: 52–58) | 33 ± 4 (95% CI: 31–35) | 52 ± 11 (95% CI: 43–61) |
| LVEF at diagnosis, % | 23 ± 7 (95% CI: 22–24) | 24 ± 7 (95% CI: 23–25) | 21 ± 7 (95% CI: 18–24) | 16 ± 4 (95% CI: 12–19) |
| NYHA class at diagnosis | 2.8 ± 0.7 (95% CI: 2.7‐2.9) | 2.7 ± 0.7 (95% CI: 2.6‐2.8) | 3.4 ± 0.7 (95% CI: 3.1‐3.6) | 3 ± 0 (NA) |
| Rhythm at diagnosis | ||||
| Sinus | 102 (87) | 77 (85) | 20 (100) | 5 (83) |
| AF | 15 (13) | 14 (15) | 0 | 1 (17) |
| HR at diagnosis, bpm | 82 ± 18 (95% CI: 79–85) | 82 ± 18 (95% CI: 79–86) | 83 ± 19 (95% CI: 74–91) | 73 ± 8 (95% CI: 66–79) |
| QRS duration at diagnosis, ms | 113 ± 27 (95% CI: 108–117) | 115 ± 26 (95% CI: 109–120) | 100 ± 26 (95% CI: 88–111) | 124 ± 26 (95% CI: 104–145) |
| NT‐proBNP at diagnosis, ng/L | 6722 ± 9351 (95% CI: 5027–8416) | 7252 ± 9787 (95% CI: 5242–9263) | 5693 ± 8370 (95% CI: 2025–9361) | 2796 ± 2422 (95% CI: 858–4734) |
| Medications | ||||
| β‐Blocker | 114 (97) | 89 (98) | 19 (95) | 6 (100) |
| ACEI/ARB | 114 (97) | 88 (97) | 20 (100) | 6 (100) |
| MRA | 107 (91) | 82 (90) | 19 (95) | 6 (100) |
| Diuretics | 97 (83) | 73 (80) | 18 (90) | 6 (100) |
| Ivabradine | 33 (28) | 17 (19) | 15 (75) | 1 (17) |
| Digitalis | 15 (13) | 14 (15) | 0 (0) | 1 (17) |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CI, confidence interval; DCM, dilative cardiomyopathy; HR, heart rhythm; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NA, not applicable; NT‐proBNP, N‐terminal pro b‐type natriuretic peptide; NYHA, New York Heart Association; PPCM, peripartum cardiomyopathy; QRS, QRS interval; SD, standard deviation.
Data are presented as n (%) or mean ± SD.